crizotinib
Sign in to saveCrizotinib, sold under the brand name Xalkori among others, is an anti-cancer medication used for the treatment of non-small cell lung carcinoma (NSCLC). Crizotinib inhibits the c-Met/Hepatocyte growth factor receptor (HGFR) tyrosine kinase, which is involved in the oncogenesis of a number of other histological forms of malignant neoplasms. It also acts as an ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene 1) inhibitor.
Article
10 sectionsContents
- Medical uses
- Mechanism of action
- Society and culture
- Legal status
- Research
- Lung cancer
- Lymphomas
- Other cancers
- References
- External links
Crizotinib, sold under the brand name Xalkori among others, is an anti-cancer medication used for the treatment of non-small cell lung carcinoma (NSCLC). Crizotinib inhibits the c-Met/Hepatocyte growth factor receptor (HGFR) tyrosine kinase, which is involved in the oncogenesis of a number of other histological forms of malignant neoplasms. It also acts as an ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene 1) inhibitor.
== Medical uses == Crizotinib is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) or relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive.
Connections
Categories
2-Aminopyridines4-Piperidinyl compoundsChlorobenzene derivativesCYP3A4 inhibitorsDrugboxes which contain changes to verified fieldsDrugboxes which contain changes to watched fieldsDrugs developed by MerckDrugs developed by PfizerDrugs with non-standard legal statusECHA InfoCard ID from WikidataEthersFluorobenzene derivatives